TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04847947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
Study: NCT05443542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Game to be played is a commercially available VR game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Sodoku, crossword puzzles
Study: NCT05835934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HSK21542
Description: A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
Study: NCT05421130

Intervention type: DEVICE
Group type: OTHER
Intervention: Selective Cerebral Perfusion Catheter
Description: This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
Study: NCT05711160

Intervention type: DIAGNOSTIC_TEST
Intervention: Plaster models
Description: The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.

Intervention type: DIAGNOSTIC_TEST
Intervention: CBCT images
Description: All patients have been undergoing CBCT scans for both jaws
Study: NCT05103566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore
Description: Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
Study: NCT06415877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Episio Training
Description: episio repair training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Episio Training
Description: episio repair training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Episio Training
Description: episio repair training
Study: NCT05371860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omit breast radiation
Description: Omit breast radiation for 3 years after surgery
Study: NCT04770467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given by intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given by intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given by intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by intravenous administration
Study: NCT06085612

Intervention type: DIAGNOSTIC_TEST
Intervention: Automated retinal oximetry
Description: Non invasive standard examination on automated retinal oximetry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Automated retinal oximetry
Description: Non invasive standard examination on automated retinal oximetry.
Study: NCT05948397

Intervention type: DIAGNOSTIC_TEST
Intervention: Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale
Description: A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: One-hour pad test.~* the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in \<15 min- then sits or rests,~* patient walks for 30 min, including climbing one flight of stairs (up and down),~* patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~* the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and \>50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (\>75 g/24 hr) incontinence
Study: NCT05740267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Orifice Specimen Extraction
Description: After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
Study: NCT05951855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 10mg/day, orally on day 1 to 28
Study: NCT05439876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 2 mg daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 4 weeks
Study: NCT05665829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake transnasal laser-assisted surgery (TNLS)
Description: The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microlaryngeal surgery (MLS)
Description: For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
Study: NCT06102083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDI01 suspension
Description: Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDI01 suspension
Description: Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDI01 suspension
Description: Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily.
Study: NCT05653310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Tradipitant Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule
Study: NCT05711160

Intervention type: DIAGNOSTIC_TEST
Intervention: IOS images
Description: The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
Study: NCT04817839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-week post-operative activity restriction
Description: Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week post-operative activity restriction
Description: Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
Study: NCT05656469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised medication advice based on pharmacogenetic testing
Description: Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
Study: NCT05889793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emetine Hydrochloride
Description: To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant takes a placebo for 10 consecutive days.
Study: NCT05209620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
Study: NCT06215820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-02
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: over-encapsulated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: over-encapsulated tablet and/or tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: over-encapsulated tablet and/or tablet
Study: NCT06436014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing VR experience
Description: Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing VR experience
Description: Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
Study: NCT05332392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00040
Description: Noninvasive wearable health monitoring device
Study: NCT05680597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Tele-Rehabilitation Agility Boot Camp (ABC)
Description: The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
Study: NCT06289426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
Study: NCT05093569

Intervention type: DEVICE
Intervention: K'watch
Description: Patients
Study: NCT05915104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX®
Description: 9 mg delayed and extended-release tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide controlled ileal release (CR) capsules
Description: three 3 mg capsules daily oral administration for 8 weeks
Study: NCT05440344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.
Study: NCT06242106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucometer
Description: A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucometer
Description: A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
Study: NCT05685849

Intervention type: DEVICE
Intervention: Echocardiography
Description: Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
Study: NCT05679440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural interventions based on pulmonary imaging
Description: The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
Study: NCT00200889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TEAS
Description: non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TEAS
Description: non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
Study: NCT05225792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promis Physical Function Questionnaire
Description: Patient reported physical function outcomes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: L Test
Description: Performance based measure assessing general physical function and balance ability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrowing Beam Walking Test
Description: Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEQ-A
Description: Survey on confidence, stumbles and falls.
Study: NCT06380725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation(real stimulation)
Description: Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial alternating current stimulation(sham stimulation)
Description: Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
Study: NCT05359276

Intervention type: DRUG
Intervention: Olipudase alfa
Description: GZ402665
Study: NCT06417385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS soterix device
Description: Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
Study: NCT05159687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
Study: NCT06422312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cystoscopy with RedPine flexible disposable cystoscope
Description: Use of a disposable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy with standard of care flexible reusable scope
Description: Use of a reusable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents
Study: NCT05485701

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening tools for common mental disorders
Description: A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening tools for common mental disorders
Description: A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
Study: NCT05082792

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: doppler ultrasound
Description: Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks
Study: NCT05680597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Tele-Rehabilitation Agility Boot Camp (ABC)
Description: The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
Study: NCT01996501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Orally Disintegrating 5mg Tablets
Study: NCT05636683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root surface debridement
Description: subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
Study: NCT05755932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFO MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HFA MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA.
Study: NCT05353894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561 oral tablets and capsules
Description: Two formulations and Two dosage will be compared

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561 oral tablets and capsules
Description: Two formulations and Two dosage will be compared

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561 oral tablets and capsules
Description: Two formulations and Two dosage will be compared
Study: NCT06025318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™
Description: PanCytoVir™ 100 mg/mL oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™
Description: PanCytoVir™ 100 mg/mL oral suspension
Study: NCT05660356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Pfizer provided GH therapy